Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder
Lu T, Ryan D, Cadet T, Chawarski M, Coupet E, Edelman E, Hawk K, Huntley K, Jalali A, O'Connor P, Owens P, Martel S, Fiellin D, D'Onofrio G, Murphy S. Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. Annals Of Emergency Medicine 2024 PMID: 39570250, DOI: 10.1016/j.annemergmed.2024.10.001.Peer-Reviewed Original ResearchHealth care sector perspectiveImplementation facilitatorsOpioid use disorder careIncremental cost-effectiveness ratioCost-effectiveness ratioHealth care sector costsEducational strategiesImplementation facilitation strategyCost-effectiveness acceptability curvesLikelihood of cost-effectivenessCost-effectiveOpioid use disorderQuality-adjusted life yearsUse disorderPatient engagementAcademic EDED visitsAcceptability curvesStandard educationEmergency departmentLife yearsFacilitation strategiesMeasures of effectivenessHealthBuprenorphine403EMF Barriers and Facilitators to Addiction Treatment Access From the Emergency Department Among Black Individuals With Opioid Use Disorder
Coupet E, Chawarski M, Hercules K, Williams J, Murphy A, Owens P, D'Onofrio G. 403EMF Barriers and Facilitators to Addiction Treatment Access From the Emergency Department Among Black Individuals With Opioid Use Disorder. Annals Of Emergency Medicine 2024, 84: s182-s183. DOI: 10.1016/j.annemergmed.2024.08.403.Peer-Reviewed Original Research488 Impact of Housing Status and Treatment Engagement for Emergency Department Patients With Substance Use Disorders
Ryus C, Hawk K, Canty T, Maffei J, Martel S, Heckmann R, Sabounchi N, Pantalon M, D'Onofrio G. 488 Impact of Housing Status and Treatment Engagement for Emergency Department Patients With Substance Use Disorders. Annals Of Emergency Medicine 2024, 84: s216-s217. DOI: 10.1016/j.annemergmed.2024.08.478.Peer-Reviewed Original ResearchExtended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
D’Onofrio G, Herring A, Perrone J, Hawk K, Samuels E, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall M, Walsh S, Dziura J, Fiellin D. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Network Open 2024, 7: e2420702. PMID: 38976265, PMCID: PMC11231806, DOI: 10.1001/jamanetworkopen.2024.20702.Peer-Reviewed Original ResearchConceptsClinical Opiate Withdrawal ScaleExtended-release buprenorphineOpioid use disorderPrecipitated withdrawalOpioid withdrawalOpioid use disorder treatmentCow scoreClinical Opiate Withdrawal Scale scoreAdverse eventsNonrandomized trialsSevere opioid use disorderDays of opioid useOpiate Withdrawal ScaleModerate to severe opioid use disorderFormulation of buprenorphineOpioid use disorder careWithdrawal ScaleUse disorderAssociated with medicationsNonprescribed opioidsPain scoresExtended-releaseInjection painOpioid useAdult patientsTrends in the Prescribing of Buprenorphine for Opioid Use Disorder, 2019-2023
Savitz S, Stevens M, Nath B, D’Onofrio G, Melnick E, Jeffery M. Trends in the Prescribing of Buprenorphine for Opioid Use Disorder, 2019-2023. Mayo Clinic Proceedings Innovations Quality & Outcomes 2024, 8: 308-320. PMID: 38841599, PMCID: PMC11152959, DOI: 10.1016/j.mayocpiqo.2024.04.004.Peer-Reviewed Original ResearchOpioid use disorderTreat alcohol use disorderAlcohol use disorderUse disorderX-waiverMedicare Advantage enrolleesTreat opioid use disorderRate ratiosEvaluate trendsPrescribing of buprenorphineOptumLabs Data WarehouseDaily doseCommercial enrolleesCoronavirus diseasePrescription fillsBuprenorphineDays supplyBuprenorphine prescribingFilling patternBuprenorphine accessImprove buprenorphine accessStudy periodResponse to coronavirus diseasePrescriber typePrescribing